Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax COVID-19 shot have slumped.
The Food and Drug Administration approved Moderna's vaccine for respiratory syncytial virus ... nearly 45% in 2023. The FDA was initially slated to make a decision on Moderna's jab on May ...
Moderna's vaccine was approved by the FDA for the prevention of RSV-associated lower respiratory ... A positive CDC decision from the agency will allow Moderna to compete in the U.S. fall ...
Like Spikevax, mRESVIA is based on Moderna's messenger RNA platform. While mRESVIA is not the first RSV vaccine to secure FDA approval—that designation went to GSK's Arexvy—Moderna's offering ...
Moderna’s shot is the third RSV vaccine for people 60 and older that’s gotten the green light from the FDA and the first ... older using shared clinical decision-making, meaning seniors ...
The US Food and Drug Administration has approved another vaccine to help ... the two other approved RSV vaccines for adults 60 and older using shared clinical decision-making, meaning seniors ...
opens new tab respiratory syncytial virus (RSV ... Moderna had filed for FDA approval in July on data from a late-stage trial that showed its vaccine was 84% effective at preventing those symptoms ...
Opens in a new tab or window The FDA approved the first-ever mRNA-1345 vaccine (mRESVIA) for respiratory syncytial virus (RSV) for people ages 60 and older to protect against lower respiratory ...